Know Cancer

or
forgot password

A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Advanced Sarcoma

Thank you

Trial Information

A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma

Inclusion Criteria


Metastatic and /or unresectable disease state after previous standard chemotherapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

toxicities

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Jonathan Lewis, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

ZIOPHARM Oncology, Inc

Authority:

United States: Food and Drug Administration

Study ID:

IPM2001

NCT ID:

NCT00439686

Start Date:

February 2006

Completion Date:

March 2008

Related Keywords:

  • Advanced Sarcoma
  • Sarcoma

Name

Location

Fountain Valley, California  92708
Flint, Michigan  48532